Precision BioSciences Q1 net loss $20.6M; revenue drops to <$0.1M; PBGENE-DMD accelerated

PRECISION BIOSCIENCES INC

2025-Q1 EPS reported -$2.21 revenue$29,000

Revenue less than $0.1M vs $17.6M in Q1 2024; net loss of $20.6M ($2.21/share) vs net income $8.6M ($1.70/share) a year ago.
Cash, equivalents and restricted cash ~$100M; cash runway expected into H2 2026, funding PBGENE-HBV and PBGENE-DMD through Phase 1 data.
PBGENE-HBV cleared for U.S. Phase 1 (FDA IND) and UK (MHRA); Fast Track designation granted; initial safety data presented at EASL.
PBGENE-DMD prioritized as second wholly owned program; IND/CTA target in 2025 with clinical data expected in 2026.
PBGENE-3243 development paused to focus resources on HBV and DMD programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.